Merck(US:MRK) ZACKSยท2024-10-28 14:21Core Viewpoint - Merck (MRK) is expected to report a quarterly earnings decline of 29.6% year over year, with earnings per share (EPS) projected at $1.50, while revenues are forecasted to increase by 3.7% to $16.54 billion [1]. Earnings Estimates - The consensus EPS estimate has been revised downward by 2.1% over the past 30 days, indicating a reassessment by analysts [1][2]. - Revisions to earnings estimates are significant indicators for predicting investor actions regarding the stock [2]. Key Metrics Forecast - Analysts predict 'Sales- Oncology- Alliance Revenue- Lynparza' at $346.03 million, reflecting a year-over-year increase of 15.7% [4]. - 'Sales- Oncology- Keytruda' is expected to reach $7.38 billion, indicating a 16.5% increase from the previous year [4]. - 'Sales- Hospital Acute Care- Zerbaxa' is forecasted at $59.30 million, showing an 11.9% year-over-year change [4]. Additional Sales Projections - 'Sales- Oncology- Alliance revenue- Lenvima' is estimated at $275.08 million, with a year-over-year change of 5.8% [5]. - 'Sales- Hospital Acute Care- Bridion - U.S.' is projected to be $309.22 million, reflecting a 16.7% increase year over year [5]. - 'Sales- Oncology- Keytruda - International' is expected to be $2.93 billion, indicating a 15.2% increase [6]. Regional Sales Insights - 'Sales- Oncology- Alliance revenue- Lynparza - U.S.' is projected at $168.05 million, with a 9.8% year-over-year change [7]. - 'Sales- Oncology- Alliance revenue- Lynparza - International' is expected to reach $177.98 million, reflecting a 21.9% increase [7]. - 'Sales- Oncology- Alliance revenue- Lenvima - U.S.' is forecasted at $180.66 million, indicating a 12.9% increase [8]. - 'Sales- Hospital Acute Care- Zerbaxa - U.S.' is expected to be $32.48 million, reflecting a 12% increase year over year [9]. Stock Performance - Merck shares have decreased by 8.5% over the past month, contrasting with the Zacks S&P 500 composite's increase of 2% [9].